What Ethicon Endo-Surgery does

Ethicon Endo-Surgery is a medical device division of Johnson & Johnson, operating within J&J MedTech's Surgery franchise and headquartered in Cincinnati, Ohio. It develops, manufactures, and sells surgical instruments, wound closure products, biosurgical hemostats, surgical staplers, energy-based devices, antimicrobial dressings, surgical instruments, and an emerging line of robotics and digital surgery solutions for minimally invasive and open surgical procedures. The portfolio is organized around six product categories — wound closure, biosurgery (anchored by the SURGICEL absorbable hemostat line), surgical stapling (Echelon platform), surgical energy, antimicrobial dressings (Biopatch with CHG), and surgical instruments — and is sold under more than 135 years of Johnson & Johnson surgical heritage.

The business serves a broad base of healthcare facilities and professionals across ten surgical specialties: bariatric, cardiovascular, colon and rectal, gynecology, head and neck, interventional pulmonology, orthopaedics, plastic, thoracic, and veterinary surgery. Its go-to-market is an enterprise field-sales model in which representatives provide product demonstrations, in-service training, and clinical support directly to hospitals, ambulatory surgical centers, and specialty clinics worldwide, supplemented by a multi-channel HCP education infrastructure (education library, learning programs, in-person and virtual events, research and evidence) and a phone-based technical support line. Revenue is generated through quote-based hardware sales negotiated via healthcare procurement processes, typically structured as multi-year contracts with hospital systems, with no public pricing disclosure.

As a wholly-owned division of a publicly traded parent (NYSE: JNJ), Ethicon Endo-Surgery does not raise external capital, has no independent headcount or revenue disclosure, and operates under J&J MedTech's global regulatory, manufacturing, and distribution infrastructure. Strategic activity on record includes the 2011 acquisition of SterilMed and the more recent extension of the portfolio into robotics and digital surgery solutions.

Name

Ethicon Endo-Surgery

Legal name

Johnson & Johnson (Ethicon Endo-Surgery operating as division of J&J MedTech)

Website

https://ethiconendosurgery.com

Company type

Public

Operating status

Operating

Short description

Ethicon Endo-Surgery, a division of Johnson & Johnson MedTech, develops and sells surgical devices for minimally invasive and open procedures. Its portfolio spans wound closure, hemostats, stapling, energy platforms, antimicrobial dressings, surgical instruments, and digital solutions, serving hospitals and surgical centers across multiple specialties.

Ownership category

akta.pro rank

Product category

Surgical Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS) (HLAHADAA)

akta.pro secondary industries

Surgical Stapling, Suturing & Hemostasis (Staplers, Clips, Sealants, Tourniquets) (HLAHADAL), Single-Use Surgical Devices & Procedure Packs (Disposable instruments, drapes, kits) (HLAHADAM), Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN)

Keywords

• Surgical instruments
• Wound closure devices
• Biosurgery hemostats
• Surgical stapling devices
• Antimicrobial dressings

Headquarters

HQ city

Cincinnati

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: Ethicon Endo-Surgery generates revenue through the sale of surgical instruments, wound closure products, biosurgery solutions (hemostats), surgical stapling devices, surgical energy products, and antimicrobial dressings to hospitals, surgical centers, and healthcare facilities worldwide.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Ethicon Endo-Surgery develops, manufactures, and sells medical devices for minimally invasive and open surgical procedures. Its portfolio spans wound closure solutions, adjunctive absorbable hemostats (including SURGICEL Powder and the SURGICEL Endoscopic Applicator), surgical stapling instruments, surgical energy platforms, antimicrobial dressings (Biopatch Protective Disk with CHG), surgical instruments, and robotics and digital surgery solutions. Products are sold to hospitals, surgical centers, and healthcare professionals across bariatric, cardiovascular, colon and rectal, gynecology, head and neck, interventional pulmonology, orthopaedics, plastic, thoracic, and veterinary surgical specialties.

Product overview

Ethicon Endo-Surgery, operating under J&J MedTech, offers a comprehensive portfolio of surgical products organized into six main categories: Wound Closure (tissue sealing and healing solutions), Biosurgery (hemostatic agents including SURGICEL™ Powder Absorbable Hemostat), Surgical Stapling (instruments for tissue approximation), Surgical Energy (electrosurgical devices), Antimicrobial Dressings (including Biopatch with CHG), and Surgical Instruments. The company has over 135 years of experience driving innovations in surgical care, serving multiple surgical specialties including bariatric, cardiovascular, colon & rectal, gynecology, head & neck, interventional pulmonology, orthopaedics, plastic, thoracic, and veterinary procedures.

Differentiator

Problem solved

Functional benefit

Brands

• SURGICEL: Absorbable hemostat product line for surgical bleeding control
• Echelon

Products and services

• SURGICEL Powder Absorbable Hemostat

Quantifiable outcome

• Surgical complications (infections, bleeding, wound reopening) impact millions globally - the company is advancing standards for safer surgery

Segments10 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators3 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Stryker: Major competitor across surgical instruments and energy devices, with overlapping presence in orthopedic and ENT surgical specialties. Stryker's instrument and power-tool lines compete directly with Ethicon's surgical instruments category.
• Intuitive Surgical: Dominant robotic-assisted surgery platform whose da Vinci ecosystem shifts procedural volume and instrument consumption toward robotic-compatible vendors. A defining structural competitor for the long-term share of Ethicon's open and laparoscopic surgical instrument business.
• Conmed: Mid-cap surgical device company offering advanced energy, electrosurgery, and general surgical instruments used by the same hospital and ASC customers Ethicon targets. Direct overlap in surgical energy and instrument categories.
• Medtronic: Direct competitor in surgical stapling, surgical energy, and minimally invasive instruments across many of the same specialties Ethicon serves. Medtronic's diversified portfolio and Hugo robotic ecosystem compete head-to-head with Ethicon's stapling and energy franchises.
• Becton, Dickinson and Company (BD): Competes with Ethicon in surgical instrumentation, biosurgery, and infection-prevention products. BD's Bard acquisition and surgical platform overlap directly with Ethicon's hemostasis, wound closure, and antimicrobial dressing franchises.
• Applied Medical: Private competitor focused on minimally invasive surgical devices, trocars, and wound closure products. Directly comparable portfolio overlap in laparoscopic instrumentation and stapling-adjacent categories.
• Olympus: Major surgical endoscopy and energy device competitor serving many of the same surgical specialties, particularly in interventional pulmonology, colorectal, and urology where Ethicon markets endoscopic applicators and energy devices.
• Teleflex: Sells surgical instruments, ligation devices, and access products used across open and minimally invasive procedures, with overlap in general surgery, colorectal, and gynecologic specialties where Ethicon is also active.

Broad incumbents

• Integra LifeSciences: Broader surgical and wound care incumbent with regenerative tissue and dural repair products. Comparable to Ethicon's wound closure and biosurgery categories and competes for similar hospital and specialty surgeon customers.
• Smith+Nephew: Broader medical device incumbent with significant presence in orthopedic and sports medicine surgery. Overlap with Ethicon's orthopedics specialty and adjacent wound management portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ethicon Endo-Surgery